The safety and adverse event profile of topiramate

Reviews in Contemporary Pharmacotherapy

Volumn 10, Issue 3, 1999, Pages 185-191

  Lhatoo, S D ^a   Walker, M C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBONATE DEHYDRATASE INHIBITOR; SULFONAMIDE; TOPIRAMATE;

AMNESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; FAMILY HISTORY; HEADACHE; HUMAN; LIVER FAILURE; MAJOR CLINICAL STUDY; NEPHROLITHIASIS; NEUROPSYCHIATRY; NONHUMAN; PARESTHESIA; REVIEW; SOMNOLENCE; TERATOGENICITY; VERTIGO; WEIGHT REDUCTION;

EID: 0032699654     PISSN: 09548602     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (21)

1. Abou-Khalil B, YOL Topiramate Study Group. Topiramate therapy in the long-term management of epilepsy. Epilepsia 1997; 38 (Suppl 3): 60.
2. Bauer G, Crawford P, Canger R, YOL-E Study Group. Open label, long-term topiramate therapy for epilepsy. Epilepsia 1997; 38 (Suppl 3): 58-59.
3. Ben-Menachem E. Potential antiepileptic drugs: topiramate. In: Levy RH, Mattson RH, Meldrum BS, eds. Antiepileptic drugs. 4th edn. New York: Raven Press, 1995: 1063-1070.
4. Ben-Menachem E, Henriksen O, Dam M et al. Double-blind, placebo-controlled trial of topiramate as add-on therapy in patients with refractory partial seizures. Epilepsia 1996; 37: 539-543.
5. Biton V. Preliminary open label experience with topiramate in primary generalized seizures. Epilepsia 1997; 38 (Suppl 1): S42-S-44.
6. Bjoro K, Gjerstad L, Bentdal O, Osnes S, Schrumpf E. Topiramate and fulminant hepatic failure. Lancet 1998; 352: 1119.
7. Canger R, Avanzini G, Tartara A et al. Long-term efficacy and tolerability of topiramate add-on therapy: interim analysis after four years of treatment. Epilepsia 1997; 38 (Suppl 3): 59.
8. Edwards KR, Kamin M. The beneficial effect of slowing the initial titration rate of topiramate. Neurology 1997; 48: A39.
9. Faught E, Wilder BJ, Ramsay RE et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996; 46: 1684-1690.
10. Gilliam FG, Veloso F. Tolerability of topiramate as monotherapy in patients with recently diagnosed partial epilepsy. Epilepsia 1998; 39 (Suppl 6): 56.
11. Gubbay SS. The occurrence of drug-induced myopia as a transient side effect of topiramate. Epilepsia 1998; 39: 451.
12. Janssen-Cilag. Topiramate monograph. Macclesfield, UK: Gardner Caldwell Communications Ltd, 1998a.
13. Janssen-Cilag. Clinical Study Report. Evaluation of two titration rates of Topamax - efficacy and safety. Data on file 2. Saunderton: Janssen-Cilag, 1998b.
14. Rosenfeld W, Abou-Khalil B, Reife R, Hegadus R, Pledger G, Topiramate YF/YG Study Group. Placebo-controlled trial of topiramate as adjunctive therapy to carbamazapine or phenytoin for partial-onset epilepsy. Epilepsia 1996; 37 (Suppl 5): 153.
15. Rosenfeld WE, Sachdeo RC, Faught RE, Privitera M. Long-term experience with topiramate as adjunctive therapy and as monotherapy in patients with partial onset seizures: retrospective study of open-label treatment. Epilepsia 1997a; 38 (Suppl 1): S34-S36.
16. Rosenfeld WE, Schaefer PA, Pace K. Weight loss patterns with topiramate therapy. Epilepsia 1997b; 38 (Suppl 3): 58.
17. Sachdeo RC, Reife RA, Lim P, Pledger G. Topiramate monotherapy for partial onset seizures. Epilepsia 1997; 38: 294-300.
18. Sander JWAS. New drugs for epilepsy. Curr Opin Neurol 1998; 11: 141-148.
19. Scott DF. The history of epilepsy. Carnforth: Parthenon, 1993.
20. Scott WJ, Hirsch KS, DeSesso JM, Wilson JG. Comparative studies on acetazolamide teratogenesis in pregnant rats, rabbits and rhesus monkeys. Teratology 1981; 24: 37-42.
21. Shank RP, Gardocki JF, Vaught JL et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994; 35: 450-460.